Nintedanib

NINTEDANIB was first approved for use in the United States in 2014. Used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. Indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer (NSCLC). Plasma protein binding of nintedanib is high, with a bound fraction of 97.8%; Albumin is thought to be the major binding protein. Orally active potent tyrosine kinase inhibitor. No dosage titration is required.

Therapy Area: Medicine
Form: Oral Capsule
Packaging: 3x1x10

COMPOSITION:

Nintedanib 100mg/ 150mg capsule

MODE OF ACTION:

Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these kinases and blocks the intracellular signaling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodeling in interstitial lung diseases.

INDICATIONS

  • Idiopathic Pulmonary Fibrosis
  • Chronic Fibrosing Interstitial Lung Diseases (ILDs)
  • Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
  • Non-small Cell Lung Cancer

Dosage

1 Capsule Twice a Day

  • Full dose: 150 mg twice daily (preferably 12 hours apart at the same time of the day)
  • Low dose: 100 mg twice daily (if not tolerable to 150 mg dose)

Disclaimer:

This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About NINTECARE

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.